Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road
96-Year-Old Originator 'Kept Faith'
Executive Summary
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.
You may also be interested in...
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs
Japan will raise reimbursement prices for selected essential and clinically valuable drugs in April, while cutting back prices for a higher than usual number of other products through the broad application of market expansion repricing rules. The overall regular revision will see prices cut by 4.7% on average.
Deal Watch: Biogen, AbCellera Team To Find Novel Way To Cross Blood-Brain Barrier
Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.